Picture loading failed.

Anti-VWF therapeutic antibody (Pre-made Caplacizumab biosimilar,Nanobody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-093-1mg 1mg 3090
GMP-Bios-ab-093-10mg 10mg 21890
GMP-Bios-ab-093-100mg 100mg 148000
GMP-Bios-ab-093-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-VWF therapeutic antibody (Pre-made Caplacizumab biosimilar,Nanobody)
INN Name Caplacizumab
TargetVWF
FormatNanobody
DerivationHumanized
Species ReactivityHuman
CH1 Isotypena
VD LCna
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAblynx
Conditions ApprovedThrombotic thrombocytopenic purpura
Conditions Activena
Conditions DiscontinuedThrombosis
Development TechNanobody Technology